73 1.2.2.a, p.75 ,
93 1.5.1. Peptide ?-amyloïde 1-40 (A? 40 ), Synucléine, p.102 ,
109 1.1. Sélection des patients, p.112 ,
Classification des d??mences??: aspects nosologiques, M??decine Nucl??aire, vol.31, issue.6, pp.278-293, 2007. ,
DOI : 10.1016/j.mednuc.2007.04.005
Syndrome d??mentiel??: diagnostic et prise en charge, EMC - Trait?? de m??decine AKOS, vol.5, issue.2, pp.5-0745 ,
DOI : 10.1016/S1634-6939(10)52283-X
Alzheimer's disease : a public health problem : yes, but a priority, Rev Neurol (Paris), vol.158, pp.311-326, 2002. ,
Alzheimer et les troubles apparentés. Rapport OPEPS n°2454, Juillet, 2005. ,
La prise en charge de la maladie d'Alzheimer et des maladies apparentées, p.256, 2005. ,
The role of ??-amyloid peptide in neurodegenerative diseases, Ageing Research Reviews, vol.10, issue.4 ,
DOI : 10.1016/j.arr.2011.03.002
G??n??tique de la maladie d???Alzheimer??: formes autosomiques dominantes, Revue Neurologique, vol.165, issue.3, pp.223-231, 2009. ,
DOI : 10.1016/j.neurol.2008.10.019
Genome-Wide Association Studies in Alzheimer Disease, Archives of Neurology, vol.65, issue.3, 2008. ,
DOI : 10.1001/archneur.65.3.329
Tauopathie et Maladie d'Alzheimer, un processus dégénératif à part entière, Psychol neuropsychiatr Vieil, vol.4, pp.261-73, 2006. ,
A Prospective Study of Alzheimer Disease in Down Syndrome, Archives of Neurology, vol.46, issue.8, pp.849-853, 1989. ,
DOI : 10.1001/archneur.1989.00520440031017
Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PloS One, e10659 -[15] Dartigues JF, 2010. ,
Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers., Journal of Medical Genetics, vol.32, issue.8 ,
DOI : 10.1136/jmg.32.8.642
Prévention de la maladie d'Alzheimer, NPG, vol.6, issue.36, pp.12-22, 2006. ,
The Role of Apoliprotein E in Alzheimer's Disease. Neuron, 2009. ,
Facteur de risque vasculaire et maladie d'Alzheimer. La revue de médecine interne, pp.288-291, 2003. ,
DOI : 10.1016/s0248-8663(03)80685-9
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, vol.19, issue.pt 3, pp.82-102, 2010. ,
DOI : 10.1007/BF03325209
Maladie d'Alzheimer : prendre en compte les facteurs de risque et pathologies cardiovsculaires. La revue de médecine interne, pp.21-31, 2006. ,
DOI : 10.1016/j.revmed.2005.04.037
Association of diabetes mellitus and dementia: The Rotterdam Study, Diabetologia, vol.39, issue.11, pp.1392-1399, 1996. ,
DOI : 10.1007/s001250050588
HDL et maladies neurod??g??n??ratives, Médecine des maladies Métaboliques, 2009. ,
DOI : 10.1016/S1957-2557(09)70103-8
Midlife overweight and obesity increase late-life dementia risk: A population-based twin study, Neurology, vol.76, issue.18, pp.1568-74, 2011. ,
DOI : 10.1212/WNL.0b013e3182190d09
Neuronutrition and Alzheimer's Disease, Journal of Alzheimer's Disease, vol.19, issue.4, pp.1123-1139 ,
DOI : 10.3233/JAD-2010-1312
Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease, Canadian Medical Association Journal, vol.178, issue.5, pp.548-556, 2008. ,
DOI : 10.1503/cmaj.070796
Influence of social network on occurrence of dementia: a community-based longitudinal study, The Lancet, vol.355, issue.9212, pp.1315-1324, 2000. ,
DOI : 10.1016/S0140-6736(00)02113-9
Revising the definition of Alzheimer's disease: a new lexicon, The Lancet Neurology, vol.9, issue.11, pp.1118-1145, 2010. ,
DOI : 10.1016/S1474-4422(10)70223-4
Plainte mnésique, trouble cognitif léger et maladie d'Alzheimer au stade prédémentiel, 2002. ,
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease, Clinical Neurology and Neurosurgery, vol.107, issue.3 ,
DOI : 10.1016/j.clineuro.2004.10.011
Crit??res diagnostiques des troubles cognitifs l??gers dans une cohorte de 100??patients, Revue Neurologique, vol.165, issue.12, pp.1062-1070, 2009. ,
DOI : 10.1016/j.neurol.2009.03.011
Diagnosis and biomarkers of predementia in Alzheimer's disease, BMC Medicine, vol.23, issue.1, p.89, 2010. ,
DOI : 10.1146/annurev.publhealth.23.100901.140525
Research criteria for the diagnostis of Alzheimer's disease : revising the NINCDS-ADRDA criteria, Lancet Neurol, 2007. ,
Soins palliatifs et maladie d'Alzheimer. La revue de médecine interne, pp.501-507, 2009. ,
DOI : 10.1016/j.revmed.2008.09.010
Maladie d'Alzheimer et maladies apparentées : vers un diagnostic plus précis et précoce. La revue de médecine interne, pp.86-853, 1931. ,
DOI : 10.1016/j.revmed.2010.08.006
Neuropathology of Alzheimer's Disease, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, vol.65, issue.1, pp.32-42, 2010. ,
DOI : 10.1212/WNL.53.5.902
Regional weight loss of the cerebral cortex and some subcortical nuclei in senile dementia of the Alzheimer type, Acta Neuropathologica, vol.103, issue.5, pp.509-521, 1988. ,
DOI : 10.1007/BF00687139
Histopathologie de la maladie d'Alzheimer. Morphologie, pp.199-201, 2007. ,
DOI : 10.1016/j.morpho.2007.10.010
Données fondamentales sur les pathologies amyloïdes et Tau dans la maladie d'Alzheimer : quelles perspectives thérapeutiques? Annales Pharmaceutiques Françaises, pp.136-153, 2009. ,
DOI : 10.1016/j.pharma.2009.01.002
Maladie d'Alzheimer. EMC Neurologie, 2007. ,
Neuropathologie morphologique et mol??culaire de la maladie d???Alzheimer, Annales Pharmaceutiques Fran??aises, vol.67, issue.2, pp.127-135, 2009. ,
DOI : 10.1016/j.pharma.2009.01.001
Targeted proteomics in Alzheimer???s disease: focus on amyloid-??, Expert Review of Proteomics, vol.78, issue.2, pp.225-237, 2008. ,
DOI : 10.1021/ac052263n
Oligomerization Partially Explains the Lowering of A??42 in Alzheimer???s Disease Cerebrospinal Fluid, Neurodegenerative Diseases, vol.6, issue.4 ,
DOI : 10.1159/000225376
A? Oligomers ? a decade of discovery, Journal of Neurochemistry, vol.279, issue.5, pp.1172-84, 2007. ,
DOI : 10.1038/nn1630
Biochemistry of Tau in Alzheimer???s disease and related neurological disorders, Expert Review of Proteomics, vol.6, issue.2, pp.207-231, 2008. ,
DOI : 10.1186/1471-2288-7-40
La maladie d'Alzheimer : une tauopathie parmi d'autres? Médecine, Sciences, vol.18, pp.727-763, 2002. ,
Neuropathological stageing of Alzheimer-related changes, Acta Neuropathologica, vol.80, issue.4, pp.239-59, 1991. ,
DOI : 10.1007/978-3-642-70644-8_2
Trends Neurosci, pp.428-461, 1998. ,
A grading system of Alzheimer disease lesions in neocortical areas, Neurobiology of Aging, vol.24, issue.4, pp.563-72, 2003. ,
DOI : 10.1016/S0197-4580(02)00134-3
The progression of the lesions in Alzheimer disease: insights from a prospective clinicopathological study, J Neural Transm Supp, vol.53, pp.119-145, 1998. ,
DOI : 10.1007/978-3-7091-6467-9_10
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease, Nature, vol.289, issue.7266, pp.916-938, 2009. ,
DOI : 10.1016/S0002-9440(10)65185-1
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, vol.34, issue.7, pp.939-983, 1984. ,
DOI : 10.1212/WNL.34.7.939
Actualit??s de la maladie d???Alzheimer, Annales Pharmaceutiques Fran??aises, vol.67, issue.2, pp.116-142, 2009. ,
DOI : 10.1016/j.pharma.2008.11.004
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline, European Journal of Neurology, vol.46, issue.1, pp.1-26, 2007. ,
DOI : 10.1212/WNL.54.12.2205
Démarche diagnostique devant un syndrome démentiel. La revue de médecine interne, pp.363-75, 2004. ,
DOI : 10.1016/j.revmed.2003.07.003
Aspects cliniques de??la??maladie d'Alzheimer, La Presse M??dicale, vol.36, issue.10, p.10, 2007. ,
DOI : 10.1016/j.lpm.2007.04.024
évaluation neuropsychologique dans le cadre des démences neurodégénératives. Illustration avec la maladie d'Alzheimer. Pratiques psychologiques. 11, pp.307-324, 2005. ,
Imagerie de la maladie d???Alzheimer??: IRM et imagerie fonctionnelle, Morphologie, vol.91, issue.295, pp.202-208, 2007. ,
DOI : 10.1016/j.morpho.2007.10.011
Imagerie c??r??brale du vieillissement normal : contraste avec la maladie d???Alzheimer, Revue Neurologique, vol.164, pp.102-107, 2008. ,
DOI : 10.1016/S0035-3787(08)73299-5
PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiology of Aging, vol.29, issue.10, pp.1456-65, 2008. ,
DOI : 10.1016/j.neurobiolaging.2007.03.029
EFNS guidelines for the diagnosis and management of Alzheimer???s disease, European Journal of Neurology, vol.65, issue.Suppl 3, pp.1236-1284, 2010. ,
DOI : 10.1212/01.wnl.0000167607.63000.38
Vers un diagnostic biologique de la maladie d'Alzheimer et des syndromes apparentés. La revue de médecine interne, pp.785-93, 2008. ,
DOI : 10.1016/j.revmed.2008.01.029
Démence à corps de Lewy. EMC Neurologie, 2007. ,
Alzheimer's disease : vascular etiology and pathology, Ann NY Acad Sci, vol.977, pp.1-526, 2002. ,
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, vol.51, issue.6, pp.1546-54, 1998. ,
DOI : 10.1212/WNL.51.6.1546
Démences frontotemporales. EMC Neurologie, 2007. ,
DOI : 10.1016/s0246-0378(07)43820-9
Atrophies focales. EMC Neurologie, 2010. ,
DOI : 10.1016/s0246-0378(10)26710-6
Alzheimer's Disease : The Pros and Cons of Pharmaceutical, Nutritional, Botanical, and Stimulatory Therapies, with a Discussion of Treatment Strategies from the Perspective of Patients and Pratictionners. Alternative medicine review, pp.223-267, 2010. ,
Le bon usage du médicament dans la prise en charge du patient Alzheimer Perspectives et recommandations. Le pharmacien hospitalier, Sept, vol.44, issue.1, pp.5-9, 2009. ,
The secretases: enzymes with therapeutic potential in Alzheimer disease, Nature Reviews Neurology, vol.21, issue.2, pp.99-107, 2010. ,
DOI : 10.1016/S0925-4439(00)00043-0
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease, Ann Neurol, 1995. ,
Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-Linked Immunosorbent Assay, Journal of Neurochemistry, vol.40, issue.5, pp.1828-1862, 1993. ,
DOI : 10.1002/ana.410220412
Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients, Neuroscience Letters, vol.320, issue.3, pp.156-60, 2002. ,
DOI : 10.1016/S0304-3940(02)00047-2
Cerebrospinal fluid tau, A??, and phosphorylated tau protein for the diagnosis of Alzheimer's disease, Journal of Cellular Physiology, vol.72, issue.1, pp.39-46, 2006. ,
DOI : 10.1046/j.1471-4159.1999.0720741.x
Tau and phosphorylated tau, APOE epsilon4 allele and MCI type in progressive MCI, Neurobiol Aging, 2007. ,
Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-Linked Immunosorbent Assay, Journal of Neurochemistry, vol.40, issue.5, pp.1828-1862, 1993. ,
DOI : 10.1002/ana.410220412
CSF markers for pathogenic processes in Alzheimer???s disease: diagnostic implications and use in clinical neurochemistry, Brain Research Bulletin, vol.61, issue.3, pp.235-277, 2003. ,
DOI : 10.1016/S0361-9230(03)00086-8
Total and phosphorylated tau protein as biological markers of Alzheimer???s disease, Experimental Gerontology, vol.45, issue.1, pp.30-40, 2010. ,
DOI : 10.1016/j.exger.2009.10.010
CSF Total tau, A??42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease, Molecular Neurobiology, vol.24, issue.1-3, pp.87-97, 2001. ,
DOI : 10.1385/MN:24:1-3:087
Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx, pp.213-238, 2004. ,
Les marqueurs biochimiques du LCR : un outil diagnostique de la maladie d???Alzheimer, NPG Neurologie - Psychiatrie - G??riatrie, vol.7, issue.37, pp.25-29, 2007. ,
DOI : 10.1016/S1627-4830(07)89957-0
Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls, Neuroscience Letters, vol.277, issue.1, pp.21-25, 1999. ,
DOI : 10.1016/S0304-3940(99)00845-9
Cerebrospinal Fluid ??-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain, Archives of Neurology, vol.66, issue.3, pp.382-391, 2009. ,
DOI : 10.1001/archneurol.2008.596
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals : Implication for future clinical trials of Alzheimer's disease, EMBO Mol Med, vol.1, pp.8-9371, 2009. ,
Longitudinal Study of CSF Biomarkers in Patient with Alzheimer's Disease. PloS One, Jul, vol.174, issue.7, pp.6294-94, 2009. ,
Advances in the development of biomarkers for Alzheimer???s disease: from CSF total tau and A??1???42 proteins to phosphorylated tau protein, Brain Research Bulletin, vol.61, issue.3, pp.243-53, 2003. ,
DOI : 10.1016/S0361-9230(03)00087-X
Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett, pp.133-138, 1999. ,
Reduced CSF carboxyterminally truncated A?? peptides in frontotemporal lobe degenerations, Journal of Neural Transmission, vol.313, issue.11, pp.621-629, 2007. ,
DOI : 10.1212/WNL.54.10.1960
CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, vol.70, issue.Issue 19, Part 2, pp.1827-1845, 2008. ,
DOI : 10.1212/01.wnl.0000311445.21321.fc
CSF diagnosis of Alzheimer???s disease and dementia with Lewy bodies, Journal of Neural Transmission, vol.313, issue.11, pp.1771-1779, 2006. ,
DOI : 10.1212/WNL.56.4.576
Tauopathies and synucleinopathies: Do cerebrospinal fluid ??-amyloid peptides reflect disease-specific pathogenesis?, Journal of Neural Transmission, vol.54, issue.Suppl 12, pp.919-946, 2007. ,
DOI : 10.1212/01.WNL.0000046581.81650.D0
The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease, Neurobiology of Aging, vol.30, issue.11, pp.1834-1875, 2009. ,
DOI : 10.1016/j.neurobiolaging.2008.01.013
Cerebrospinal fluid biomarkers in Creutzfeldt???Jakob disease, Clinical Neurology and Neurosurgery, vol.107, issue.5, pp.355-60, 2005. ,
DOI : 10.1016/j.clineuro.2004.12.002
Transient increase un total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, 2001. ,
Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia, Coll Antropol, vol.32, issue.1, pp.31-37, 2008. ,
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis, Clinical Chemistry and Laboratory Medicine, vol.14, issue.3, pp.353-56, 2011. ,
DOI : 10.1258/acb.2009.008232
Les marqueurs biologiques prot??iques du liquide c??phalorachidien??: caract??ristiques et implications cliniques dans les d??mences, Revue Neurologique, vol.165, issue.3, pp.213-235, 2009. ,
DOI : 10.1016/j.neurol.2008.05.004
Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease, Arch Gen Psychiatry, 2004. ,
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization, Neuroscience Letters, vol.285, issue.1, pp.49-52, 2000. ,
DOI : 10.1016/S0304-3940(00)01036-3
CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies, Journal of Neurology, Neurosurgery & Psychiatry, vol.80, issue.9, pp.966-75, 2009. ,
DOI : 10.1136/jnnp.2008.167791
CSF Biomarkers, Annals of the New York Academy of Sciences, vol.7, issue.Suppl 3, pp.28-35, 2009. ,
DOI : 10.1212/01.WNL.0000156914.16988.56
Biological markers of amyloid ??-related mechanisms in Alzheimer's disease, Experimental Neurology, vol.223, issue.2, pp.334-380, 2010. ,
DOI : 10.1016/j.expneurol.2009.09.024
Neurochemical diagnosis of Alzheimer???s dementia by CSF A??42, A??42/A??40 ratio and total tau, Neurobiology of Aging, vol.25, issue.3, pp.273-81, 2004. ,
DOI : 10.1016/S0197-4580(03)00086-1
Amyloid-?? oligomers are inefficiently measured by enzyme-linked immunosorbent assay, Annals of Neurology, vol.1, issue.1, pp.147-50, 2005. ,
DOI : 10.1016/S0925-4439(00)00030-2
High-molecular-weight ??-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients, The FASEB Journal, vol.24, issue.8, pp.2716-2742, 2010. ,
DOI : 10.1001/archneurol.2008.565
A Specific Enzyme-Linked Immunosorbent Assay for Measuring ??-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease, Archives of Neurology, vol.66, issue.2, pp.190-99, 2009. ,
DOI : 10.1001/archneurol.2008.565
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment, Journal of the Neurological Sciences, vol.251, issue.1-2, 2006. ,
DOI : 10.1016/j.jns.2006.09.014
CSF markers for incipient Alzheimer's disease. Lancet Neurol, 2003. ,
Amyloid ?? and APP as biomarkers for Alzheimer???s disease, Experimental Gerontology, vol.45, issue.1, pp.23-32, 2010. ,
DOI : 10.1016/j.exger.2009.08.002
?-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Annals of Neurology, vol.70, issue.2, pp.263-270, 2003. ,
DOI : 10.1136/jnnp.70.6.744
Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies, International Journal of Alzheimer's Disease, vol.7, issue.4, pp.2010-536 ,
DOI : 10.1002/prca.200700081
Combined Analysis of CSF Tau, A?42, A?1?42% and A?1?40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia, Int J Alzheimers Dis, 2010. ,
The cognitive profil and CSF biomarkers in dementia with Lewy bodies and Parkinson disease dementia, Int J Geriatr Psychiatry, vol.26100, issue.1, p.5, 2011. ,
CSF amyloid ??38 as a novel diagnostic marker for dementia with Lewy bodies, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.2, pp.160-164, 2011. ,
DOI : 10.1136/jnnp.2009.199398
URL : https://hal.archives-ouvertes.fr/hal-00589971
Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration, Journal of Neurology, Neurosurgery & Psychiatry, vol.78, issue.7, pp.735-742, 2007. ,
DOI : 10.1136/jnnp.2006.105064
Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-??<sub>38/40/42</sub> in Frontotemporal Dementias and Primary Progressive Aphasias, Dementia and Geriatric Cognitive Disorders, vol.31, issue.1, pp.37-44, 2011. ,
DOI : 10.1159/000322370
Decreased ??-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Neurology, vol.54, issue.5, pp.1099-102, 2000. ,
DOI : 10.1212/WNL.54.5.1099
Decreased CSF-??-Amyloid 42 in Alzheimer???s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of ??-Amyloid Induced by Disparate Mechanisms, Dementia and Geriatric Cognitive Disorders, vol.13, issue.2, pp.112-120, 2002. ,
DOI : 10.1159/000048642
Monitoring the amyloid beta-peptide in vivo ??? caveat emptor, Drug Discovery Today, vol.14, issue.5-6, pp.5-6241, 2009. ,
DOI : 10.1016/j.drudis.2008.12.004
Low cerebrospinal fluid ??-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment, Neuroscience Letters, vol.314, issue.1-2, pp.33-39, 2001. ,
DOI : 10.1016/S0304-3940(01)02285-6
Highly conserved and disease-specific patterns of carboxyterminally truncated A?? peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation, Journal of Neurochemistry, vol.92, issue.3, pp.481-96, 2002. ,
DOI : 10.1073/pnas.92.20.9141
Evaluation of Cerebrospinal Fluid Tau/Beta-Amyloid(42) Ratio as Diagnostic Markers for Alzheimer Disease, European Neurology, vol.62, issue.6, pp.349-55, 2009. ,
DOI : 10.1159/000241881
Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42, Arch Neurol, vol.60, issue.9, pp.1202-1208, 2003. ,
Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic, Dementia and Geriatric Cognitive Disorders, vol.29, issue.6, pp.491-497, 2010. ,
DOI : 10.1159/000313534
Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment, The Lancet Neurology, vol.2, issue.1, pp.15-21, 2003. ,
DOI : 10.1016/S1474-4422(03)00262-X
Biomarkers of the Dementia, International Journal of Alzheimer's Disease, vol.9, issue.7, 2011. ,
DOI : 10.1007/s00401-008-0456-1
Value of CSF ??-amyloid1???42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment, Molecular Psychiatry, vol.24, issue.7, pp.705-715, 2004. ,
DOI : 10.1016/S0197-4580(03)00002-2
Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers, Mechanisms of Ageing and Development, vol.127, issue.2, pp.129-161, 2006. ,
DOI : 10.1016/j.mad.2005.09.022
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, The Lancet Neurology, vol.5, issue.3 ,
DOI : 10.1016/S1474-4422(06)70355-6
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment, JAMA, vol.302, issue.4, pp.385-93, 2009. ,
DOI : 10.1001/jama.2009.1064
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study, The Lancet Neurology, vol.8, issue.7, pp.619-646, 2009. ,
DOI : 10.1016/S1474-4422(09)70139-5
Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type, Archives of Neurology, vol.66, issue.5, pp.638-683, 2009. ,
DOI : 10.1001/archneurol.2009.55
Cerebrospinal Fluid tau/beta- Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults, Arch Neurol, 2007. ,
Cerebrospinal fluid beta-amyloid 1-42 concentration may predict coginitive decline in older women, J Neurol Neurosurg Psychiatry, 2007. ,
Biomarkers for Alzheimer's disease therapeutic trials Pertinence des critères d'évaluation utilisés dans les essais cliniques sur la maladie d'Alzheimer, Prog Neurobiol Thérapie Mai, vol.64, issue.3, pp.139-182, 2009. ,
Alzheimer : biomarqueurs, nouveaux schémas d'études, phases précoces -[147 Biomarkers for the early stages of clinical development in Alzheimer's disease. Therapie, Table Ronde n°2 : Maladie d, pp.285-90, 2010. ,
Diagnostic biologique de la maladie d???Alzheimer??: avanc??es, limites et perspectives, Revue Neurologique, vol.165, issue.6-7, pp.6-7511, 2009. ,
DOI : 10.1016/j.neurol.2008.10.015
Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades, Neurology, vol.55, issue.12, pp.1854-62, 2000. ,
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiology of Aging, vol.29, issue.8, pp.1143-59, 2008. ,
DOI : 10.1016/j.neurobiolaging.2007.02.016
Effects of Processing and Storage Conditions on Amyloid ?? (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice, Clinical Chemistry, vol.51, issue.1, pp.189-95, 2005. ,
DOI : 10.1373/clinchem.2004.039735
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimer Dement, 2011. ,
Correlations between soluble ??/?? forms of amyloid precursor protein and A??38, 40, and 42 in human cerebrospinal fluid, Brain Research, vol.1357, pp.175-83, 2010. ,
DOI : 10.1016/j.brainres.2010.08.022
Amyloid ? peptide ratio 42/40 but not A?42 correlates with phospho-Tau in patients with low- and high-CSF A?40 load, Journal of Neurochemistry, vol.6, issue.4, pp.1053-1062, 2007. ,
DOI : 10.1002/ana.10661
Prediction of Alzheimer???s Disease Using the CSF A??42/A??40 Ratio in Patients with Mild Cognitive Impairment, Dementia and Geriatric Cognitive Disorders, vol.163, issue.5, pp.316-336, 2007. ,
DOI : 10.1148/radiology.148.3.6878708
Plasma and Cerebrospinal Fluid Levels of Amyloid ?? Proteins 1-40 and 1-42 in Alzheimer Disease, Archives of Neurology, vol.57, issue.1, pp.100-105, 2000. ,
DOI : 10.1001/archneur.57.1.100
Biomarkers in Alzheimer???s Disease, Frontiers in Neurology, vol.2, p.46, 2011. ,
DOI : 10.3389/fneur.2011.00046
Quantification of amyloid-beta 40 in cerebrospinal fluid, Journal of Immunological Methods, vol.348, issue.1-2, pp.57-66, 2009. ,
DOI : 10.1016/j.jim.2009.06.011
Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers, Neurobiology of Aging, vol.33, issue.8, 2011. ,
DOI : 10.1016/j.neurobiolaging.2011.05.013
Amyloid-?? Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines, Journal of Alzheimer's Disease, vol.20, issue.2, pp.637-683, 2010. ,
DOI : 10.3233/JAD-2010-1397
CSF Biomarkers for Alzheimer's Disease Diagnosis, International Journal of Alzheimer's Disease, vol.34, issue.6, 2010. ,
DOI : 10.1016/S1474-4422(07)70178-3
Biomarkers of Alzheimer's disease. Neurobiol Dis, 2009. ,
The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia, Current Alzheimer Research, vol.7, issue.5, pp.470-476, 2010. ,
DOI : 10.2174/156720510791383796
Magnetic Resonance Imaging Improves Cerebrospinal Fluid Biomarkers in the Early Detection of Alzheimer's Disease, Journal of Alzheimer's Disease, vol.16, issue.2, pp.351-62, 2009. ,
DOI : 10.3233/JAD-2009-0968
CSF amyloid-betapeptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia, Brain, 2006. ,
An Alzheimer's disease-specific ??-amyloid fragment signature in cerebrospinal fluid, Neuroscience Letters, vol.409, issue.3, pp.215-224, 2006. ,
DOI : 10.1016/j.neulet.2006.09.044
Mechanisms of A?? mediated neurodegeneration in Alzheimer's disease, The International Journal of Biochemistry & Cell Biology, vol.40, issue.2, pp.181-98, 2008. ,
DOI : 10.1016/j.biocel.2007.07.013
From The Cover: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease, Proceedings of the National Academy of Sciences, vol.53, issue.4, pp.2273-2279, 2005. ,
DOI : 10.1007/978-3-7091-6467-9_11
Characterisation of two antibodies to oligomeric A?? and their use in ELISAs on human brain tissue homogenates, Journal of Neuroscience Methods, vol.176, issue.2, pp.206-218, 2009. ,
DOI : 10.1016/j.jneumeth.2008.09.002
Watersoluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains, J Biol Chem. Feb, vol.23271, issue.8, pp.4077-81, 1996. ,
The Levels of Soluble versus Insoluble Brain A?? Distinguish Alzheimer's Disease from Normal and Pathologic Aging, Experimental Neurology, vol.158, issue.2, pp.328-365, 1999. ,
DOI : 10.1006/exnr.1999.7085
The role of alpha-synuclein in neurotransmission and synaptic plasticity, Journal of Chemical Neuroanatomy, vol.42, issue.4, 2010. ,
DOI : 10.1016/j.jchemneu.2010.12.001
Cerebrospinal fluid ?synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett, Feb, vol.6450, issue.3, pp.332-337, 2009. ,
Detection of elevated levels of ??-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, vol.75, issue.20, pp.1766-72, 2010. ,
DOI : 10.1212/WNL.0b013e3181fd613b
Differential levels of ??-synuclein, ??-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease, Journal of Neurology, Neurosurgery & Psychiatry, vol.81, issue.6, pp.608-618, 2010. ,
DOI : 10.1136/jnnp.2009.197483
CSF ??-synuclein levels in dementia with Lewy bodies and Alzheimer's disease, Brain Research, vol.1251, pp.1-6, 2009. ,
DOI : 10.1016/j.brainres.2008.11.055
CSF ?-synuclein as a diagnostic biomarker for Parkinson disease and related demantias, Neurology Nov, vol.1675, issue.20, pp.1760-1761, 2010. ,
Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies, Parkinsonism & Related Disorders, vol.16, issue.5, pp.307-322, 2010. ,
DOI : 10.1016/j.parkreldis.2010.02.015
??-Synuclein, A?? and Alzheimer's disease, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.27, issue.1, pp.103-111, 2003. ,
DOI : 10.1016/S0278-5846(02)00339-1
??-synuclein induced synapse damage is enhanced by amyloid-??1-42, Molecular Neurodegeneration, vol.5, issue.1, pp.1-42 ,
DOI : 10.1186/1750-1326-5-55
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potentiel biomarker for Parkinson's disease ,
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice, Arch neurol, 2001. ,
Low frequency of post-lumbar puncture headache in demented patients ,
Safety and Acceptability of the Research Lumbar Puncture, Alzheimer Disease & Associated Disorders, vol.19, issue.4, pp.220-225, 2005. ,
DOI : 10.1097/01.wad.0000194014.43575.fd
Douleurs induites par les soins chez la personne âgée, Douleurs, vol.9, pp.22-27, 2008. ,
DOI : 10.1016/s1624-5687(08)70529-8
The normal equilibrum between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett, pp.127-158, 2007. ,
Clearance of amyloid-?? by circulating lipoprotein receptors, Nature Medicine, vol.23, issue.9, pp.1029-1060, 2007. ,
DOI : 10.1016/S0002-9440(10)62995-1
Platelets Are the Primary Source of Amyloid ??-Peptide in Human Blood, Biochemical and Biophysical Research Communications, vol.213, issue.1, pp.96-103, 1995. ,
DOI : 10.1006/bbrc.1995.2103
The amyloid precursor protein of Alzheimer disease in human brain and blood, Journal of Leukocyte Biology, vol.66, issue.4, pp.567-74, 1999. ,
DOI : 10.1002/jlb.66.4.567
Plasma A?? Levels Do Not Reflect Brain A?? Levels, Journal of Neuropathology & Experimental Neurology, vol.148, issue.4, pp.264-71, 2007. ,
DOI : 10.1016/S1474-4422(06)70501-4
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease, J Neurosci. Jan15, vol.21, issue.2, pp.372-81, 2001. ,
Plasma beta amyloid and the risk of Alzheimer disease and demantia in elderly men: a prospective, population-based cohort study ,
Plasma A??42 and A??40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study, Journal of Neurology, Neurosurgery & Psychiatry, vol.81, issue.10, pp.1123-1130, 2010. ,
DOI : 10.1136/jnnp.2010.205757
Plasma A??1???40 and A??1???42 and the risk of dementia: a prospective case-cohort study, The Lancet Neurology, vol.5, issue.8, pp.655-60, 2006. ,
DOI : 10.1016/S1474-4422(06)70501-4
Association of Low Plasma A??42/A??40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease, Archives of Neurology, vol.64, issue.3, pp.354-62, 2007. ,
DOI : 10.1001/archneur.64.3.354
The clinical significance of plasmatic amyloidAbeta40 peptide levels in Alzheimer's disease patients treated with galantamine. Am J Alzheimers Dis Other Dement, pp.286-90, 2008. ,
Biomarkers of Alzheimer disease in plasma, NeuroRX, vol.2, issue.2, pp.226-260, 2004. ,
DOI : 10.1038/nrd1130
Quelle place pour les biomarqueurs dans le diagnostic de la maladie d'Alzheimer et des maladies apparentés, Psychol Neurol Psychiatr.Vieil, vol.8, issue.1, pp.25-31, 2010. ,
Circulating biomarkers of cognitive decline and dementia, Clinica Chimica Acta, vol.364, issue.1-2, pp.91-112, 2006. ,
DOI : 10.1016/j.cca.2005.06.015
Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease, Neurobiol Aging, vol.20, issue.2, p.247, 1999. ,
Longitudinal study of cerebrospinal fluid levels of tau, A?1-40, and A?1-42(43) in Alzheimer's disease: A study in Japan, Annals of Neurology, vol.37, issue.1, pp.17-26, 1998. ,
DOI : 10.1212/WNL.47.5.1113
Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P, Neurochemistry International, vol.55, issue.4, pp.214-222, 2009. ,
DOI : 10.1016/j.neuint.2009.02.017
A?1-42 dans le LCR : Propositions d'arbres décisionnels pour l'aide au diagnostic des démences et de la MA, Revue Neurologique, vol.165, pp.71-72, 2009. ,